# DESCRIPTION

## FIELD OF INVENTION

- define antigen-binding proteins

## BACKGROUND OF THE INVENTION

- describe limitations of monoclonal antibodies

## SUMMARY OF THE INVENTION

- introduce bispecific antigen-binding protein
- describe heterodimer formation
- detail CH1 region modification
- specify S40T and T47S mutations
- describe CH1 region selection
- specify human IgG1, IgG2, IgG3, and IgG4
- describe CH2 and CH3 domain selection
- specify immunoglobulin light chain
- describe CDR composition
- specify human heavy chain
- describe variable domain composition
- specify human framework region
- describe phage library screening
- describe immunization and antibody identification
- specify humanized antibody
- describe bispecific antibody affinity
- specify non-immunogenic heavy chain
- describe proteolysis and T-cell epitope avoidance

## DETAILED DESCRIPTION

- motivate bispecific antibody formats
- describe advantages of bispecific antibodies
- summarize limitations of monovalent antibody therapeutics
- introduce bispecific T cell Engager (BiTE) molecules
- describe disadvantages of BiTE format
- introduce hybrid mouse-rat monoclonal antibody format
- describe disadvantages of hybrid format
- introduce "knobs-into-holes" strategy for bispecific antibody production

### EXAMPLES

- describe binding experiments with CaptureSelect IgG-CH1 affinity reagent
- identify sequence determinants responsible for IgG binding to CaptureSelect IgG-CH1 affinity reagent
- modify human CH1 domain to alter binding to CH1 affinity chromatography media
- describe purification of differentially modified IgG1
- generate and purify anti-IL17 x anti-CD3 bispecific antibody
- characterize interaction of IgG bearing modified and unmodified CH1 domains using surface Plasmon resonance

## OTHER EMBODIMENTS

- indicate that other aspects, advantages, and modifications are within the scope of the invention

